Evidence map›Paper›PMID 29061842›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2018

Endothelial nitric oxide synthase modulates Toll-like receptor 4-mediated IL-6 production and permeability via nitric oxide-independent signaling.

Ryan J Stark, Stephen R Koch, Hyehun Choi, Eric H Mace, Sergey I Dikalov, Edward R Sherwood, Fred S Lamb

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ryan J StarkDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Stephen R KochDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Hyehun ChoiDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Eric H MaceDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Sergey I DikalovDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; and.
Edward R SherwoodDepartment of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Fred S LambDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Vanderbilt University · US

Funding

Training Innate Immunity: A new approach to the treatment of SepsisR01GM119197 · NIGMS · EAST TENNESSEE STATE UNIVERSITY · PI SHERWOOD, EDWARD R, WILLIAMS, DAVID L. · 2016 to 2024
$4.6M
Ductus Arteriosus Regulation by Anion ChannelsR01HL128386 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LAMB, FRED S, REESE, JOHN JEFFREY · 2016 to 2019
$2.3M
Sirtuin 3 Impairment and SOD2 Acetylation in Oxidative Stress and HypertensionR01HL124116 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DIKALOV, SERGEY · 2015 to 2018
$1.6M
Augmentation of Innate Anti-Microbial Immunity by TLR4 AgonistsR01GM104306 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ENKHBAATAR, PERENLEI, SHERWOOD, EDWARD R · 2013 to 2016
$1.2M
Prevention of Endothelial Injury by Toll-like Receptor 4 ModulatorsK08GM117367 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STARK, RYAN J · 2015 to 2018
$734k
LSM880-Airyscan Confocal Microscope for Large Shared ResourceS10OD021630 · OD · VANDERBILT UNIVERSITY · PI WELLS, K. SAM · 2016 to 2016
$560k
NHLBI NIH HHS R01 HL128386NIGMS NIH HHS K08 GM117367NIGMS NIH HHS R01 GM104306NIGMS NIH HHS R01 GM119197NIH HHS S10 OD021630
6 · The paper itself

Abstract

Endothelial dysfunction, characterized by changes in eNOS, is a common finding in chronic inflammatory vascular diseases. These states are associated with increased infectious complications. We hypothesized that alterations in eNOS would enhance the response to LPS-mediated TLR4 inflammation. Human microvascular endothelial cells were treated with sepiapterin or N-nitro-L-arginine methylester (L-NAME) to alter endogenous NO production, and small interfering RNA to knockdown eNOS. Alterations of endogenous NO by sepiapterin, and L-NAME provided no significant changes to LPS inflammation. In contrast, eNOS knockdown greatly enhanced endothelial IL-6 production and permeability in response to LPS. Knockdown of eNOS enhanced LPS-induced p38. Inhibition of p38 with SB203580 prevented IL-6 production, without altering permeability. Knockdown of p38 impaired NF-κB activation. Physical interaction between p38 and eNOS was demonstrated by immunoprecipitation, suggesting a novel, NO-independent mechanism for eNOS regulation of TLR4. In correlation, biopsy samples in patients with systemic lupus erythematous showed reduced eNOS expression with associated elevations in TLR4 and p38, suggesting an in vivo link. Thus, reduced expression of eNOS, as seen in chronic inflammatory disease, was associated with enhanced TLR4 signaling through p38. This may enhance the response to infection in patients with chronic inflammatory conditions.-Stark, R. J., Koch, S. R., Choi, H., Mace, E. H., Dikalov, S. I., Sherwood, E. R., Lamb, F. S. Endothelial nitric oxide synthase modulates Toll-like receptor 4-mediated IL-6 production and permeability via nitric oxide-independent signaling.

Indexed as

Capillary PermeabilityMAP Kinase Signaling SystemCells, CulturedChronic DiseaseEndothelial CellsGene Expression Regulation, EnzymologicHumansImidazolesInterleukin-6LipopolysaccharidesNitric OxideNitric Oxide Synthase Type IIIp38 Mitogen-Activated Protein KinasesPyridinesToll-Like Receptor 4VasculitisIL6 protein, humanImidazolesInterleukin-6LipopolysaccharidesNitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanp38 Mitogen-Activated Protein KinasesPyridinesSB 203580TLR4 protein, humanToll-Like Receptor 4endothelial cellseNOSinflammationp38TLR-4

Identifiers

PMID29061842
PMCPMC5888395
OpenAlexW2766375586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.